Dual pd-l1 and ctla4 inhibition in es-sclc

Access through your institution Buy or subscribe In March 2020, the FDA approved the anti-PD-L1 antibody durvalumab in combination with first-line platinum–etoposide chemotherapy for

extensive-stage small-cell lung cancer (ES-SCLC), based on interim overall survival (OS) data from the phase III CASPIAN trial. Updated results of this trial confirm the benefit of this

combination (median OS 12.9 months versus 10.5 months with chemotherapy alone; HR 0.75; nominal _P_ = 0.003). However, a primary analysis of OS in a third arm of this trial showed no benefit

from adding both durvalumab and the anti-CTLA4 antibody tremelimumab to chemotherapy: median 10.4 months versus 10.5 months with chemotherapy alone (HR 0.82; _P = _0.05). This finding might

reflect the increased incidence of toxicities with the tremelimumab-containing regimen and related reductions in overall levels of exposure to both durvalumab and chemotherapy. This is a

preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value

online-access subscription $32.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more

Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS:

* Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Goldman, J. W. et al. Durvalumab, with or without tremelimumab,

plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled,

open-label, phase 3 trial. _Lancet Oncol._ https://doi.org/10.1016/S1470-2045(20)30539-8 (2020) Article  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc David Killock Authors * David Killock View author publications You can also search for this author inPubMed 

Google Scholar CORRESPONDING AUTHOR Correspondence to David Killock. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Killock, D. Dual PD-L1 and CTLA4

inhibition in ES-SCLC. _Nat Rev Clin Oncol_ 18, 64 (2021). https://doi.org/10.1038/s41571-020-00466-w Download citation * Published: 21 December 2020 * Issue Date: February 2021 * DOI:

https://doi.org/10.1038/s41571-020-00466-w SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative